Vaqta

BIOLOGICAL5 trials

Sponsors

GlaxoSmithKline, Stanford University, Sanofi

Conditions

Healthy AdultsHepatitis AHepatitis BInfluenzaPneumococcal ImmunizationTyphoid

Phase 1

Effects of Aging on Primary and Secondary Vaccine Responses

CompletedNCT03312699

Stanford UniversityHealthy Adults, Hepatitis A, Influenza +1

Start: 2017-09-19End: 2023-12-31Updated: 2024-12-16

Phase 3

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruitingNCT06824181

SanofiPneumococcal Immunization

Start: 2025-02-27End: 2027-09-10Updated: 2026-02-13

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

RecruitingNCT06824194

SanofiPneumococcal Immunization

Start: 2025-02-18End: 2027-05-12Target: 2320Updated: 2026-03-03

Phase 4

Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults

CompletedNCT00603252

GlaxoSmithKlineHepatitis A, Hepatitis B

Start: 2008-01-31End: 2008-06-30Updated: 2017-03-14

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

CompletedNCT00684671

GlaxoSmithKlineHepatitis A, Hepatitis B

Start: 2008-05-26End: 2008-11-03Updated: 2018-08-17